Danaher Corporation
DHR
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $146.0B
$207.66
▼ -1.60%
P/E
36.88
Mkt Cap
$146.0B
52-Wk Range
$160.93–$242.80
52-Week Range
$160.93 - $242.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diverse technology portfolio
- Strong R&D capabilities
- Global market presence
- Proven acquisition strategy
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Increasing biotech research investments
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Strong
+11.3% over 3m
Quality
Strong
Excellent business quality
Dividend
Modest
0.69% yield
Smart-money signal
Who's buying DHR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 20, 2026
JUL 21, 2026
Reported EPS of $1.94 vs $1.85 consensus (+4.9% surprise). Revenue of $6.3B vs $6.1B expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.9%
Revenue trend · last 8Q
—
+2%
-1%
+3%
+4%
+5%
+4%
+6%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$5.8B
$6.5B
$5.7B
$5.9B
$6.1B
$6.8B
$6.0B
$6.3B
Margins · last 8Q
Gross
57.6%
Operating
18.0%
Profit
13.9%
Wall Street consensus
11 analysts · 73% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
73%
Hold
27%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jul 22, 2026
vs Industry
How DHR stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related